Compare Stocks → Your $200 account credit is about to expire (From MarketBeat) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDigital Media StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ACHLNASDAQ:AGTCNASDAQ:BCLINASDAQ:PLUR Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHLAchilles Therapeutics$0.90-2.2%$0.94$0.74▼$1.76$36.99M1.25552,865 shs59,397 shsAGTCApplied Genetic Technologies$0.39$0.39$0.23▼$2.83$26.62M1.55943,490 shsN/ABCLIBrainstorm Cell Therapeutics$0.53+2.3%$0.54$0.13▼$3.34$37.07M0.4914,441 shs116,090 shsPLURPluri$5.85-11.4%$5.94$3.45▼$8.56$31.53M1.5221,792 shs4,431 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHLAchilles Therapeutics+0.99%-2.63%+20.92%-41.46%-9.10%AGTCApplied Genetic Technologies0.00%0.00%0.00%0.00%0.00%BCLIBrainstorm Cell Therapeutics-3.80%-16.63%-3.29%+41.00%-82.42%PLURPluri+9.63%+6.28%+23.20%+5.04%+3.58%Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot NowMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACHLAchilles Therapeutics2.4513 of 5 stars3.05.00.00.03.40.80.6AGTCApplied Genetic TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ABCLIBrainstorm Cell Therapeutics1.9005 of 5 stars0.05.00.04.73.40.00.6PLURPluriN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACHLAchilles Therapeutics2.00Hold$4.00344.40% UpsideAGTCApplied Genetic TechnologiesN/AN/AN/AN/ABCLIBrainstorm Cell Therapeutics2.00HoldN/AN/APLURPluriN/AN/AN/AN/ACurrent Analyst RatingsLatest AGTC, BCLI, PLUR, and ACHL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/5/2024ACHLAchilles TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $6.004/5/2024ACHLAchilles TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$8.00 ➝ $2.00(Data available from 5/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACHLAchilles TherapeuticsN/AN/AN/AN/A$3.17 per shareN/AAGTCApplied Genetic Technologies$320K83.19N/AN/A$0.26 per share1.51BCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/A($0.08) per shareN/APLURPluri$290K108.73N/AN/A$0.34 per share17.21Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACHLAchilles Therapeutics-$69.67M-$1.60N/AN/AN/AN/A-42.95%-37.88%8/2/2024 (Estimated)AGTCApplied Genetic Technologies-$68.94M-$1.46N/AN/AN/AN/A-192.90%-92.54%N/ABCLIBrainstorm Cell Therapeutics-$17.19M-$0.32N/AN/AN/AN/AN/A-431.16%8/12/2024 (Estimated)PLURPluri-$28.32M-$4.64N/A∞N/A-6,339.59%-249.60%-50.12%6/4/2024 (Estimated)Latest AGTC, BCLI, PLUR, and ACHL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2024Q1 2024BCLIBrainstorm Cell Therapeutics-$0.07-$0.05+$0.02-$0.05N/AN/A5/8/2024Q1 2024ACHLAchilles Therapeutics-$0.46-$0.30+$0.16-$0.30N/AN/A4/4/2024Q4 2023ACHLAchilles TherapeuticsN/A-$0.46-$0.46-$0.46N/AN/A4/1/2024Q4 2023BCLIBrainstorm Cell Therapeutics-$0.15-$0.11+$0.04-$0.11N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACHLAchilles TherapeuticsN/AN/AN/AN/AN/AAGTCApplied Genetic TechnologiesN/AN/AN/AN/AN/ABCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/AN/APLURPluriN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACHLAchilles TherapeuticsN/A9.639.63AGTCApplied Genetic Technologies0.391.401.40BCLIBrainstorm Cell TherapeuticsN/A0.180.18PLURPluri13.046.056.05OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACHLAchilles Therapeutics56.38%AGTCApplied Genetic Technologies22.05%BCLIBrainstorm Cell Therapeutics14.33%PLURPluri16.59%Insider OwnershipCompanyInsider OwnershipACHLAchilles Therapeutics5.38%AGTCApplied Genetic Technologies4.10%BCLIBrainstorm Cell Therapeutics5.45%PLURPluri10.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableACHLAchilles Therapeutics20441.09 million38.88 millionNot OptionableAGTCApplied Genetic Technologies8367.63 million64.86 millionOptionableBCLIBrainstorm Cell Therapeutics2970.08 million66.26 millionOptionablePLURPluri1235.39 million4.84 millionOptionableAGTC, BCLI, PLUR, and ACHL HeadlinesRecent News About These CompaniesMay 20, 2024 | globenewswire.comNovel Medical Food Solution for the Elderly: Pluri & Wilk Collaborate to Develop Human Breast Milk-Derived Food Production on a Commercial ScaleMay 12, 2024 | finance.yahoo.comPluri Third Quarter 2024 Earnings: US$1.01 loss per share (vs US$1.53 loss in 3Q 2023)May 4, 2024 | pharmabiz.comPluri launches immunotherapy platform for solid tumour cancer treatmentMay 2, 2024 | globenewswire.comUnleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer TreatmentMay 1, 2024 | outlookindia.comDeconstructing The Muslim Question In IndiaApril 11, 2024 | msn.comPackers will face the Eagles in Brazil's first NFL game everApril 10, 2024 | uk.investing.comPluri Inc. announces breakthrough in immune cell therapy productionApril 8, 2024 | msn.comPluri stock jumps 9% on US patent for immune cell productionApril 8, 2024 | pharmaceutical-technology.comPluri launches manufacturing division as cell therapy pipeline progressesApril 8, 2024 | globenewswire.comBreakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New MethodApril 3, 2024 | investorplace.comPLUR Stock Earnings: Pluri Reported Results for Q4 2023April 1, 2024 | goodreturns.inHere is the list of companies splitting on April 1:March 29, 2024 | msn.comReAlta signs deal with NIAID to develop drug for radiation poisoningMarch 28, 2024 | finance.yahoo.comPluri’s Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming ConferencesMarch 28, 2024 | globenewswire.comPluri's Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming ConferencesMarch 27, 2024 | globenewswire.comPluri Inc. Announces 1-for-8 Reverse Share SplitMarch 21, 2024 | globenewswire.comPluri's Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market ReportMarch 19, 2024 | globenewswire.comEngage with Pluri's Talent: Exciting Conference Appearances AheadMarch 18, 2024 | european-news-agency.deTruth, justice & freedom in a pluri-anthropological worldMarch 18, 2024 | israel21c.orgYour next cup of coffee may come from a labNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAchilles TherapeuticsNASDAQ:ACHLAchilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.Applied Genetic TechnologiesNASDAQ:AGTCApplied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.Brainstorm Cell TherapeuticsNASDAQ:BCLIBrainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.PluriNASDAQ:PLURPluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.